Eyenuk is a medtech company that develops an artificial intelligence screening tool for risk assessment and disease surveillance. The company's first product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for the autonomous detection of diabetic retinopathy. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life-and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease.
The company was founded in 2010 and is based in Los Angeles, California.